Review
doi: 10.1016/j.clon.2010.04.008.
Molecular targeted therapies for patients with refractory thyroid cancer
Affiliations
- PMID: 20554167
- DOI: 10.1016/j.clon.2010.04.008
Item in Clipboard
Review
Molecular targeted therapies for patients with refractory thyroid cancer
Clin Oncol (R Coll Radiol).
2010 Aug.
Abstract
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
[Use of new molecules in the treatment of advanced thyroid cancer].Endocrinol Nutr. 2011 Oct;58(8):381-6. doi: 10.1016/j.endonu.2011.07.001. Epub 2011 Sep 15. Endocrinol Nutr. 2011. PMID: 21924966 Review. Spanish. No abstract available.
-
New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.Discov Med. 2010 Feb;9(45):153-62. Discov Med. 2010. PMID: 20193642 Review.
-
Update on thyroid cancer treatment.Future Oncol. 2012 Oct;8(10):1331-48. doi: 10.2217/fon.12.123. Future Oncol. 2012. PMID: 23130931 Review.
-
New molecular targeted therapies in thyroid cancer.Anticancer Drugs. 2006 Sep;17(8):869-79. doi: 10.1097/01.cad.0000224449.16329.c5. Anticancer Drugs. 2006. PMID: 16940797 Review.
-
Targeted therapy in radioiodine refractory thyroid cancer.Q J Nucl Med Mol Imaging. 2009 Oct;53(5):520-5. Q J Nucl Med Mol Imaging. 2009. PMID: 19910905 Review.
Cited by
-
Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience.J Clin Med. 2021 Jan 20;10(3):384. doi: 10.3390/jcm10030384. J Clin Med. 2021. PMID: 33498404 Free PMC article.
-
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.Oncotarget. 2015 Nov 3;6(34):36383-99. doi: 10.18632/oncotarget.5799. Oncotarget. 2015. PMID: 26415230 Free PMC article.
-
Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib.SAGE Open Med. 2020 Jun 12;8:2050312120930906. doi: 10.1177/2050312120930906. eCollection 2020. SAGE Open Med. 2020. PMID: 32587691 Free PMC article.
-
Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study.Front Oncol. 2023 Oct 11;13:1139659. doi: 10.3389/fonc.2023.1139659. eCollection 2023. Front Oncol. 2023. PMID: 37886165 Free PMC article.
-
Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography.Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):425-36. eCollection 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 24116351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
